Effect of low-molecular weight trypsin inhibitor, nafamostat mesilate, on trypsin activity using the pancreatic acinar cells

Pancreas

Volumn 38, Issue 5, 2009, Pages 595-597

  Hashimoto, Daisuke ^a   Ohmuraya, Masaki ^a   Wang, Jun ^a   Yamamura, Ken Ichi ^a   Hirota, Masahiko ^a   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; CERULETIDE; GABEXATE MESILATE; NAFAMSTAT MESILATE; TRYPSIN;

ACINAR CELL; ANIMAL CELL; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; DRUG HALF LIFE; DRUG PENETRATION; DRUG TISSUE LEVEL; ENZYME ACTIVATION; ENZYME ACTIVITY; LETTER; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APROTININ; CELLS, CULTURED; ENZYME ACTIVATION; GLYCOPROTEINS; GUANIDINES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR WEIGHT; PANCREAS; PROSTATIC SECRETORY PROTEINS; TRYPSIN; TRYPSIN INHIBITORS; TRYPSINOGEN;

EID: 67651122883     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31819156de     Document Type: Letter

References (10)

1. Saluja AK, Lerch MM, Phillips PA, et al. Why does pancreatic overstimulation cause pancreatitis? Annu Rev Physiol. 2007;69:249-269.
2. Leach SD, Modlin IM, Scheele GA, et al. Intracellular activation of digestive zymogens in rat pancreatic acini. Stimulation by high doses of cholecystokinin. J Clin Invest. 1991;87:362-366.
3. Takeda K, Matsuno S, Sunamura M, et al. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg. 1996;171:394-398. (Pubitemid 26105206)
4. Imaizumi H, Kida M, Nishimaki H, et al. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas. 2004;28:369-373. (Pubitemid 38509739)
5. Matsukura A, Otani T, Takamoto T, et al. Intracellular activation of trypsinogen in rat pancreatic acini after supramaximal secretagogue stimulation: cysteine protease and serine protease activity. Pancreas. 2006;32:197-204.
6. Ohmuraya M, Hirota M, Araki K, et al. Enhanced trypsin activity in pancreatic acinar cells deficient for serine protease inhibitor Kazal type 3. Pancreas. 2006;33: 104-106. (Pubitemid 43995348)
7. Hirota M, Fujimura Y, Kimura Y, et al. Protease inhibitor and protease receptor on acute pancreatitis [in Japanese]. Surg Front. 2006;13:445-453.
8. Mikami Y, Takeda K, Matsuda K, et al. Rat experimental model of continuous regional arterial infusion of protease inhibitor and its effects on severe acute pancreatitis. Pancreas. 2005;30:248-253. (Pubitemid 40397377)
9. Satoh H, Harada M, Tashiro S, et al. The effect of continuous arterial infusion of gabexate mesilate (FOY-007) on experimental acute pancreatitis. J Med Invest. 2004; 51:186-193. (Pubitemid 39610913)
10. Tsukagoshi S. Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation [in Japanese]. Gan To Kagaku Ryoho. 2000;27: 767-774.